Naval Shanware

@NavalShanware

Life science consultant ; ex-Pfizer oncology researcher, PhD Pharmacology UW-Madison; views own

Vrijeme pridruživanja: ožujak 2019.
6 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @NavalShanware

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NavalShanware

  1. proslijedio/la je Tweet
    prije 20 sati

    recorded impairment charge of $800M related to R&D acquired in its deal for Kite Pharma. Last Q4 it took a $820M impairment charge.

    6 proslijeđenih tweetova 11 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    prije 20 sati

    Yescarta sales

    7 replies 10 proslijeđenih tweetova 27 korisnika označava da im se sviđa
    Poništi
  3. proslijedio/la je Tweet
    1. velj

    Cord-blood derived CD19-CAR modified NK cells induce remissions in B cell malignancies. February 6, 2020 issue of NEJM in print. Congrats to Katy Rezvani and the whole group! Stay tuned for online issue. NK cell immunotherapy works without CRS or ICANS!

    112 proslijeđenih tweetova 245 korisnika označava da im se sviđa
    Poništi
  4. proslijedio/la je Tweet
    30. sij

    Why is tox lower in of / in ALL? - better management? - earlier Toci? - but especially earlier referral and fewer patients with highly refractory disease

    VIDEO: Real world experience of tisagenlecleucel for R/R ALL in the US w/ of :
    11 proslijeđenih tweetova 29 korisnika označava da im se sviđa
    Poništi
  5. proslijedio/la je Tweet
    30. sij

    Good illustration of how biosimilars are hitting . Novel me-too drugs are accelerating, but it's not enough.

    5 proslijeđenih tweetova 9 korisnika označava da im se sviđa
    Poništi
  6. proslijedio/la je Tweet
    29. sij

    So well-done, from the great & . So many threads saying is NBD vs flu. Flu is “a mild-mannered serial killer. The aggressive response to the coronavirus is meant to stop the new pathogen from becoming a deadlier copycat.”

    A lot of people have compared the new coronavirus to the flu. The flu is bad! What you don't want is for the coronavirus to become just like it -- and there are reasons to worry:
    Prikaži ovu nit
    11 proslijeđenih tweetova 23 korisnika označavaju da im se sviđa
    Poništi
  7. proslijedio/la je Tweet
    28. sij

    Latest from Ronny Gal at Bernstein: Biosimilars' market shares rising & prices dropping. Actual net prices even lower b/c excludes discounts and rebates. breakthrough in 2020 (Sorry, full report available only from Bernstein)

    1 reply 10 proslijeđenih tweetova 25 korisnika označava da im se sviđa
    Poništi
  8. proslijedio/la je Tweet
    27. sij

    Regeneron's Len Schleifer & George Yancopoulos presented this slide at to illustrate how far they've come since '10. From 1 approved medicine to 7 at end of '19. From $18M to $10B in net product sales. They grew from ~1000 employees to ~8000.

    1 reply 2 proslijeđena tweeta 13 korisnika označava da im se sviđa
    Poništi
  9. proslijedio/la je Tweet
    28. sij

    A sobering reminder that health care workers are heroes on the front lines of this crisis. Our hearts and thanks go out to Dr. Liang Wudong and his family.

    Doctor Liang Wudong at the ENT department of Hubei Xinhua Hospital who had been at the front line fighting against in Wuhan, died from the virus on Sat at the age of 62.
    Prikaži ovu nit
    6 replies 120 proslijeđenih tweetova 281 korisnik označava da mu se sviđa
    Poništi
  10. proslijedio/la je Tweet
    27. sij

    Lenvatinib + PD1 combo bring some of the most encouraging data at for tough to treat cancers 70% ORR in MSS Gastric cancer 77% ORR in unresectable HCC Will lucitinib achieve something similar?

    1 reply 30 proslijeđenih tweetova 56 korisnika označava da im se sviđa
    Poništi
  11. proslijedio/la je Tweet
    28. sij

    I’ve been reluctant to share this story because it’s so personal, not “professional”. But that’s really the point, isn’t it? Healthcare is exquisitely personal—whether we’re clinicians or patients or family. /1

    I know for her tireless work to illuminate the human cost of in healthcare. I didn’t know that her calling to this work began in the hospital where her husband was dying, and clinicians were too beaten down to care. via
    6 replies 18 proslijeđenih tweetova 59 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    26. sij

    This dad had more than 80 clips to pull from, selecting first the percussive ones -- sounds like thumps, coughs, the shake of a rattle. He then sorted the remaining clips by pitch. The result is astounding

    96 replies 502 proslijeđena tweeta 2.216 korisnika označava da im se sviđa
    Poništi
  13. proslijedio/la je Tweet
    24. sij

    Bummer #1/3 Encouraging science and early phase results don’t always translate to favorable results in phase III...

    17 proslijeđenih tweetova 31 korisnik označava da mu se sviđa
    Poništi
  14. proslijedio/la je Tweet
    24. sij

    IMbrave150 vs showed OS benefit and advantage will be the next issue

    1 reply 11 proslijeđenih tweetova 19 korisnika označava da im se sviđa
    Poništi
  15. proslijedio/la je Tweet
    21. sij

    Halozyme Ph3 data on Gemcitabine Abraxane & PEGPH20 vs GA alone in metastatic to be presented at on Friday. HR 1.00! The drug made absolutely no difference in HA high tumors.

    13 proslijeđenih tweetova 19 korisnika označava da im se sviđa
    Poništi
  16. proslijedio/la je Tweet
    15. sij

    Hal Barron. Years away from machine learning in biology/drug development, because our datasets are not big enough. We are doing multivariate analysis , it’s just math and 100 years old. The near future is more multivariate analysis

    5 replies 6 proslijeđenih tweetova 17 korisnika označava da im se sviđa
    Poništi
  17. proslijedio/la je Tweet
    15. sij

    This is probably the most interesting stat in 2020 E&Y Firepower Report and explains the lack of M&A at "69% of surveyed dealmakers say the valuation gap between buyers and sellers is the largest its been since 2008"

    36 proslijeđenih tweetova 99 korisnika označava da im se sviđa
    Poništi
  18. proslijedio/la je Tweet
    14. sij

    Rick Klausner: when a medical advance becomes a standard procedure, you lose the drive to innovate. Happened w dialysis and bone marrow transplant. Nowhere near there yet w adoptive cell therapy for cancer. Won't be routine procedure for a long time.

    2 proslijeđena tweeta 3 korisnika označavaju da im se sviđa
    Poništi
  19. proslijedio/la je Tweet
    14. sij

    Patrick Hwu of MD Anderson: the community has had 1800 negative immune checkpoint combo trials in a row. But most of the time those trials didn't ensure that immune cells are recognizing the cancer. When the immune cells see cancer, this strategy works.

    2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
    Poništi
  20. proslijedio/la je Tweet
    14. sij

    Still fascinates me that there is a national panel in UK to review/approve each CAR T case - is this sustainable, especially with approval expected in myeloma in 2020?

    Off to UK national DLBCL CART panel meeting. Just over 1y of meetings (most telecon!). Over 250 cases approved. Many challenges remain: - who will benefit? - is one product best? - how best to bridge? - how to treat relapses? - optimal infection proph?
    7 replies 3 proslijeđena tweeta 27 korisnika označava da im se sviđa
    Poništi

@NavalShanware još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·